

Natural Killer (NK) Cell Therapeutics Market Size, Share & Trends Analysis Report By Natural Killer (NK) cell Therapy Type (NK Cell Therapy (unmodified), CAR-NK Cell Therapy (modified), NK Cell Engager), By Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), By Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, Others), By Indication (Hepatocellular Carcinoma (HCC), Acute Myeloid Leukemia (AML), Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL), Peripheral T-Cell Lymphoma (PTCL).), By Pipeline Product (AFM13, MG4101, GTA002 (oNKordA), TAK-007) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-05-12 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Natural Killer (NK) Cell Therapeutics Market Analysis and Insights

The Natural Killer (NK) Cell Therapeutics Market size is anticipated to reach USD 92 Million in 2022 and it is projected to reach USD 3160 Million by 2031, growing at a CAGR of % during the forecast period.

The Global Natural Killer (NK) Cell Therapeutics Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

of the market segments which include types, applications, and competitor analysis.

The Global Natural Killer (NK) Cell Therapeutics Market growth, Size report provides a comprehensive analysis of the Pharmaceuticals industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Natural Killer (NK) Cell Therapeutics Market includes major supplies & Independent Consultants among others.

Global Market Scope and Natural Killer (NK) Cell Therapeutics Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Natural Killer (NK) Cell Therapeutics Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Natural Killer (NK) Cell Therapeutics Market Country Level Analysis

The Global Natural Killer (NK) Cell Therapeutics Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Natural Killer (NK) Cell Therapeutics Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Natural Killer (NK) Cell Therapeutics Market

Some of the other major highlights of the demand for Natural Killer (NK) Cell Therapeutics Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Natural Killer (NK) Cell Therapeutics Market during the forecast period.

GC Cell (GC Biopharma corp.)

ImmunityBio Inc.

Nkarta Inc.

Takeda Pharmaceutical Company Limited

Sanofi S. A.

Innate Pharma SA

Glycostem Therapeutics B. V.

Fate Therapeutics Inc.

Dragonfly Therapeutics Inc.

Cytovac A/ S.

Market Segmentation

The Global Natural Killer (NK) Cell Therapeutics Market Share, Demand provides the most up-to-date Pharmaceuticals industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Natural Killer (NK) cell Therapy Type

NK Cell Therapy (unmodified)

CAR-NK Cell Therapy (modified)

NK Cell Engager

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

By Approaches

Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Bispecific Antibodies

By Application

Cancer

Immunoproliferative Disorders

Acute Infectious Diseases

Gastrointestinal Diseases

Others

By Indication

Hepatocellular Carcinoma (HCC)

Acute Myeloid Leukemia (AML)

Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)

Peripheral T-Cell Lymphoma (PTCL).

By Pipeline Product

AFM13

MG4101

GTA002 (oNKordA)

TAK-007

Regions Coverd

North America

U.S.

Canada

Europe

U.K.

Germany

France

Spain

Italy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Russia
Nordic
Benelux
Rest of Europe

APAC

China
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa

UAE
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM

Brazil
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

- 1 Executive Summary
- 2 Research Scope & Segmentation
 - 2.1 Research Objectives
 - 2.2 Limitations & Assumptions
 - 2.3 Market Scope & Segmentation
 - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
 - 3.1 Emerging Regions / Countries
 - 3.2 Emerging Companies
 - 3.3 Emerging Applications / End Use
- 4 Market Trends
 - 4.1 Drivers
 - 4.2 Market Warning Factors
 - 4.3 Latest Macro Economic Indicators
 - 4.4 Geopolitical Impact
 - 4.5 Technology Factors
- 5 Market Assessment
 - 5.1 Porters Five Forces Analysis
 - 5.2 Value Chain Analysis
- 6 Global Natural Killer (NK) Cell Therapeutics Market Size Analysis
 - 6.1 By Natural Killer (NK) cell Therapy Type
 - 6.1.1 NK Cell Therapy (unmodified)
 - 6.1.2 CAR-NK Cell Therapy (modified)
 - 6.1.3 NK Cell Engager
 - 6.2 By Approaches
 - 6.2.1 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
 - 6.2.2 Bispecific Antibodies
 - 6.3 By Application
 - 6.3.1 Cancer
 - 6.3.2 Immunoproliferative Disorders
 - 6.3.3 Acute Infectious Diseases
 - 6.3.4 Gastrointestinal Diseases
 - 6.3.5 Others
 - 6.4 By Indication
 - 6.4.1 Hepatocellular Carcinoma (HCC)
 - 6.4.2 Acute Myeloid Leukemia (AML)
 - 6.4.3 Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
 - 6.4.4 Peripheral T-Cell Lymphoma (PTCL).
 - 6.5 By Pipeline Product
 - 6.5.1 AFM13
 - 6.5.2 MG4101
 - 6.5.3 GTA002 (oNKordA)
 - 6.5.4 TAK-007
- 7 North America Market Analysis
 - 7.1 By Natural Killer (NK) cell Therapy Type
 - 7.1.1 NK Cell Therapy (unmodified)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.2 CAR-NK Cell Therapy (modified)
- 7.1.3 NK Cell Engager
- 7.2 By Approaches
 - 7.2.1 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
 - 7.2.2 Bispecific Antibodies
- 7.3 By Application
 - 7.3.1 Cancer
 - 7.3.2 Immunoproliferative Disorders
 - 7.3.3 Acute Infectious Diseases
 - 7.3.4 Gastrointestinal Diseases
 - 7.3.5 Others
- 7.4 By Indication
 - 7.4.1 Hepatocellular Carcinoma (HCC)
 - 7.4.2 Acute Myeloid Leukemia (AML)
 - 7.4.3 Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
 - 7.4.4 Peripheral T-Cell Lymphoma (PTCL).
- 7.5 By Pipeline Product
 - 7.5.1 AFM13
 - 7.5.2 MG4101
 - 7.5.3 GTA002 (oNKordA)
 - 7.5.4 TAK-007
- 7.5 U.S.
- 7.6 Canada
- 8 Europe Market Analysis
 - 8.1 By Natural Killer (NK) cell Therapy Type
 - 8.1.1 NK Cell Therapy (unmodified)
 - 8.1.2 CAR-NK Cell Therapy (modified)
 - 8.1.3 NK Cell Engager
 - 8.2 By Approaches
 - 8.2.1 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
 - 8.2.2 Bispecific Antibodies
 - 8.3 By Application
 - 8.3.1 Cancer
 - 8.3.2 Immunoproliferative Disorders
 - 8.3.3 Acute Infectious Diseases
 - 8.3.4 Gastrointestinal Diseases
 - 8.3.5 Others
 - 8.4 By Indication
 - 8.4.1 Hepatocellular Carcinoma (HCC)
 - 8.4.2 Acute Myeloid Leukemia (AML)
 - 8.4.3 Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
 - 8.4.4 Peripheral T-Cell Lymphoma (PTCL).
 - 8.5 By Pipeline Product
 - 8.5.1 AFM13
 - 8.5.2 MG4101
 - 8.5.3 GTA002 (oNKordA)
 - 8.5.4 TAK-007

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5 U.K.
- 8.6 Germany
- 8.7 France
- 8.8 Spain
- 8.9 Italy
- 8.10 Russia
- 8.11 Nordic
- 8.12 Benelux
- 8.13 Rest of Europe
- 9 APAC Market Analysis
 - 9.1 By Natural Killer (NK) cell Therapy Type
 - 9.1.1 NK Cell Therapy (unmodified)
 - 9.1.2 CAR-NK Cell Therapy (modified)
 - 9.1.3 NK Cell Engager
 - 9.2 By Approaches
 - 9.2.1 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
 - 9.2.2 Bispecific Antibodies
 - 9.3 By Application
 - 9.3.1 Cancer
 - 9.3.2 Immunoproliferative Disorders
 - 9.3.3 Acute Infectious Diseases
 - 9.3.4 Gastrointestinal Diseases
 - 9.3.5 Others
 - 9.4 By Indication
 - 9.4.1 Hepatocellular Carcinoma (HCC)
 - 9.4.2 Acute Myeloid Leukemia (AML)
 - 9.4.3 Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
 - 9.4.4 Peripheral T-Cell Lymphoma (PTCL).
 - 9.5 By Pipeline Product
 - 9.5.1 AFM13
 - 9.5.2 MG4101
 - 9.5.3 GTA002 (oNKordA)
 - 9.5.4 TAK-007
 - 9.5 China
 - 9.6 Korea
 - 9.7 Japan
 - 9.8 India
 - 9.9 Australia
 - 9.10 Taiwan
 - 9.11 South East Asia
 - 9.12 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
 - 10.1 By Natural Killer (NK) cell Therapy Type
 - 10.1.1 NK Cell Therapy (unmodified)
 - 10.1.2 CAR-NK Cell Therapy (modified)
 - 10.1.3 NK Cell Engager
 - 10.2 By Approaches

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.1 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
- 10.2.2 Bispecific Antibodies
- 10.3 By Application
 - 10.3.1 Cancer
 - 10.3.2 Immunoproliferative Disorders
 - 10.3.3 Acute Infectious Diseases
 - 10.3.4 Gastrointestinal Diseases
 - 10.3.5 Others
- 10.4 By Indication
 - 10.4.1 Hepatocellular Carcinoma (HCC)
 - 10.4.2 Acute Myeloid Leukemia (AML)
 - 10.4.3 Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
 - 10.4.4 Peripheral T-Cell Lymphoma (PTCL).
- 10.5 By Pipeline Product
 - 10.5.1 AFM13
 - 10.5.2 MG4101
 - 10.5.3 GTA002 (oNKordA)
 - 10.5.4 TAK-007
- 10.5 UAE
- 10.6 Turkey
- 10.7 Saudi Arabia
- 10.8 South Africa
- 10.9 Egypt
- 10.10 Nigeria
- 10.11 Rest of MEA
- 11 LATAM Market Analysis
 - 11.1 By Natural Killer (NK) cell Therapy Type
 - 11.1.1 NK Cell Therapy (unmodified)
 - 11.1.2 CAR-NK Cell Therapy (modified)
 - 11.1.3 NK Cell Engager
 - 11.2 By Approaches
 - 11.2.1 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
 - 11.2.2 Bispecific Antibodies
 - 11.3 By Application
 - 11.3.1 Cancer
 - 11.3.2 Immunoproliferative Disorders
 - 11.3.3 Acute Infectious Diseases
 - 11.3.4 Gastrointestinal Diseases
 - 11.3.5 Others
 - 11.4 By Indication
 - 11.4.1 Hepatocellular Carcinoma (HCC)
 - 11.4.2 Acute Myeloid Leukemia (AML)
 - 11.4.3 Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
 - 11.4.4 Peripheral T-Cell Lymphoma (PTCL).
 - 11.5 By Pipeline Product
 - 11.5.1 AFM13
 - 11.5.2 MG4101

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.5.3 GTA002 (oNKordA)
- 11.5.4 TAK-007
- 11.5 Brazil
- 11.6 Mexico
- 11.7 Argentina
- 11.8 Chile
- 11.9 Colombia
- 11.10 Rest of LATAM
- 12 Competitive Landscape
- 12.1 Global Natural Killer (NK) Cell Therapeutics Market Share By Players
- 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
- 13.1 American International Industries (GIGI)
- 13.1.1 Overview
- 13.1.2 Business Information
- 13.1.3 Revenue
- 13.1.4 ASP
- 13.1.5 Swot Analysis
- 13.1.6 Recent Developments
- 13.2 ImmunityBio Inc.
- 13.3 Nkarta Inc.
- 13.4 Takeda Pharmaceutical Company Limited
- 13.5 Sanofi S. A.
- 13.6 Innate Pharma SA
- 13.7 Glycostem Therapeutics B. V.
- 13.8 Fate Therapeutics Inc.
- 13.9 Dragonfly Therapeutics Inc.
- 13.10 Cytovac A/ S.
- 14 Research Methodology
- 14.1 Research Data
- 14.1.1 Secondary Data
- 14.1.1.1 Major secondary sources
- 14.1.1.2 Key data from secondary sources
- 14.1.2 Primary Data
- 14.1.2.1 Key data from primary sources
- 14.1.2.2 Breakdown of primaries
- 14.1.3 Secondary And Primary Research
- 14.1.3.1 Key industry insights
- 14.2 Market Size Estimation
- 14.2.1 Bottom-Up Approach
- 14.2.2 Top-Down Approach
- 14.2.3 Market Projection
- 14.3 Research Assumptions
- 14.3.1 Assumptions
- 14.4 Limitations
- 14.5 Risk Assessment
- 15 Appendix

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1 Discussion Guide
- 15.2 Customization Options
- 15.3 Related Reports
- 16 Disclaimer

Natural Killer (NK) Cell Therapeutics Market Size, Share & Trends Analysis Report By Natural Killer (NK) cell Therapy Type (NK Cell Therapy (unmodified), CAR-NK Cell Therapy (modified), NK Cell Engager), By Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), By Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, Others), By Indication (Hepatocellular Carcinoma (HCC), Acute Myeloid Leukemia (AML), Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL), Peripheral T-Cell Lymphoma (PTCL).), By Pipeline Product (AFM13, MG4101, GTA002 (oNKordA), TAK-007) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-05-12 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

□** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-22"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com